Sorrento Therapeutics Inc Equity-NMS: SRNE

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :

$0.0008

What is the share price of Sorrento Therapeutics Inc today?

Sorrento Therapeutics Inc (SRNE) share price as of January 1, 1970, is $. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of Sorrento Therapeutics Inc?

Yes, Indian Investors can invest in the Sorrento Therapeutics Inc (SRNE) Share by opening an international trading account with Angel One.

How can I purchase Sorrento Therapeutics Inc shares in India?

Purchasing Sorrento Therapeutics Inc (SRNE) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying Sorrento Therapeutics Inc (SRNE) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of Sorrento Therapeutics Inc?

Yes, you can purchase fractional shares of Sorrento Therapeutics Inc (SRNE) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of Sorrento Therapeutics Inc?

The market capitalization of Sorrento Therapeutics Inc on January 1, 1970, is $0.

What documents are required to invest in Sorrento Therapeutics Inc stocks?

In order to invest in Sorrento Therapeutics Inc (SRNE) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

Sorrento Therapeutics, Inc. is a clinical-stage, antibody-centric, biopharmaceutical company developing therapies to treat cancers and COVID-19. The Company’s segments include Sorrento Therapeutics and Scilex. Sorrento Therapeutics segment is organized around Immune-Oncology therapeutic area, leveraging its G-MAB antibody library and targeted delivery modalities to generate cancer therapeutics. The Scilex segment is largely organized around its non-opioid pain management operations. The Company’s immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), clinical- stage immuno-cellular therapies (CAR-T, DAR-T), antibody-drug conjugates (ADCs) and clinical-stage oncolytic virus (Seprehvir). The Company is also developing potential antiviral therapies and vaccines against coronaviruses, including Abivertinib, COVI-AMG, COVISHIELD, COVI-MSC and COVIDROPS, and diagnostic test solutions, including COVITRACK and COVISTIX.